Rhythm Pharmaceuticals, Inc. (RYTM): Total Assets
$480.20M
As of 2025-12-31
$437.27M
As of 2026-06-30
+7.9%
3-year compound annual growth
+20.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $480.20M | +22.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $392.27M | +17.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $332.75M | -13.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $382.48M | +16.1% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $329.52M | +76.1% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $187.07M | -39.4% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $308.52M | +18.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $260.21M | +71.5% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $151.74M | n/m | 2019-03-08, Balance as of period end |
| 2016-12-31 | $12.34M | n/a | 2018-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗